ClinicalTrials.gg
Enrolling by invitationNCT06428838Updated Sep 30, 2026

Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

A Phase 3 interventional study of Eptinezumab and Standard of Care in Migraine and Chronic Migraine, sponsored by Dr George Medvedev. Enrolling by invitation at 2 sites in Canada. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Dr George Medvedev · Phase 3, Interventional, and Prevention

Updated Sep 30, 2026Now Enrolling by invitationStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Planned enrollment
18th of 21
102 · median 193
Started
2025
the only one that year
Phase 3
13 of 21
5 open now
Registered
18th of 21
by date
Lead sponsor
1 of 21
Dr George Medvedev

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 18th largest by planned enrollment, is the only one that started in 2025, is one of 13 in phase 3, and was the 18th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED.

Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptinezumab can rapidly interrupt the migraine process, potentially also preventing migraine from coming back in the short term.

Most patients with a diagnosis of migraine have no access to preventative therapies. This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack. Administering this medication in the ED may stop the attack more effectively compared to current therapies.

This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED. The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED, what other medications they might need alongside eptinezumab, and how they feel overall.

03

Conditions studied

  • Migraine
  • Chronic Migraine

Keywords

  • acute treatment
  • emergency
  • monoclonal antibody
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults between the ages of 19-75 with a history of migraines, as established at the time of presentation to the ED or known from the patient's chart;
  2. Presenting to the emergency department with a migraine that meets ICHD-3 migraine headache criteria;
  3. Provided signed ;
  4. Sufficient literacy and cognitive capacity to understand and complete patient self-rated questionnaires in English.

Exclusion criteria

Exclusion Criteria:

  1. Secondary headaches caused by an injury or underlying illness, such as a concussion, bleeding in the brain, an infection or a brain tumor
  2. Current or history of severe cardiovascular disease or renal dysfunction
  3. A systemic condition in the stage of active treatment (vasculitis, etc.)
  4. Pregnant or at risk of becoming pregnant (absent )
  5. Currently enrolled in another drug trial
  6. Dosed with eptinezumab within the past 3 months
  7. Currently on anti-CGRP therapy with monoclonal antibodies
  8. Currently involved in active litigation
  9. Any other condition which, in the opinion of the Investigator, would exclude the participant due to reasons of safety or data integrity
  10. to the active substance or to any of the
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
102 participants (estimated)

Study arms

  • Other
    Standard of Care

    SoC will be delivered at the discretion of the treating physician

    Other: Standard of Care

  • Experimental
    Standard of Care + Eptinezumab

    In addition to standard of care, participants randomized to the Standard of Care + Eptinezumab arm will receive a single infusion of eptinezumab (100mg/mL).

    Biological: Eptinezumab · Other: Standard of Care

Interventions

  • BiologicalEptinezumab

    The study treatment consists of a single infusion of eptinezumab (100mg/mL).

  • OtherStandard of Care

    SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.

06

What researchers measure

Primary outcomes

  1. Number of migraine days at week 1

    Number of migraine days at week 1, as reported in daily Headache Diary

    Time frame: Baseline to Week 1

Secondary outcomes

  1. Readmission to the Emergency Department (ED)

    Readmission to the Emergency Department (ED) as assessed by patient chart

    Time frame: Baseline to Month 3

  2. Generalized Anxiety Disorder 7-item (GAD-7)

    The Generalized Anxiety Disorder 7-item (GAD-7) will be assessed at baseline, month 1 and month 3. The GAD-7 is a short self-report questionnaire assessing the severity of anxiety disorder. For each item, the participant is asked how bothered they have been by the problem in the last 2 weeks. The total score ranges from 0-21, and a score greater than 15 indicates severe anxiety. The recall period for the GAD-7 is 2 weeks.

    Time frame: Baseline to Month 3

  3. Headache Impact Test (HIT-6)

    The Headache Impact Test (HIT-6) will involve an assessment at baseline and at months 1 and 3. The HIT-6 (v1.0) is a Likert-type, self-reported questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. HIT-6 scores range from 36 to 78. Higher scores indicate a greater impact of headaches on the respondent's life, i.e., 36 = no impact, 78 = maximum impact. The HIT-6 consists of six items: pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. The assessment was developed to measure a wide spectrum of factors contributing to headache burden, and it has demonstrated reliability and validity. The recall period for the HIT-6 is 4 weeks.

    Time frame: Baseline to Month 3

  4. Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a short self-report questionnaire assessing signs and symptoms of depression. The questionnaire consists of nine items which ask about the frequency and severity of depressive symptoms based on DSM-IV criteria. For each item, the participant is asked to rate the severity of the symptom on a scale from 0 to 3. The total score ranges from 0-27 with a higher score indicating more severe depressive symptoms. The recall period for the PHQ-9 is 2 weeks.

    Time frame: Baseline to Month 3

  5. Patient Global Impression of Change (PGI-C)

    The PGI-C will involve an assessment at 24-72hrs, week 1, month 1 and month 3. PGI-C is a one-item measure rating of the overall patient perceived improvement on a seven-point scale. Patients rate their change since treatment initiation as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse.

    Time frame: Baseline to Month 3

  6. Number of monthly headache days

    Number of monthly headache days as assessed by the Migraine Disability Assessment (MIDAS)

    Time frame: Baseline to Month 3

  7. Migraine recurrence

    Recurrence of migraine as reported in daily Headache Diary

    Time frame: Baseline to Month 3

  8. Work Productivity and Activity Impairment (WPAI)

    The WPAI is a six-item validated instrument that measures aspects of work productivity and activity impairment due to migraine over the past 7 days with higher values, in the form of percentages, indicating greater impairment due to the respondent's health. Only patients that are currently employed (full-time, part-time, or self-employed) are eligible to respond to the items assessing work-related activities. Item 6 in the WPAI will be administered to those not in employment, providing the possibility of calculating activity impairment for patients that are not employed. The six items are used to derive four subscales: Absenteeism (proportion of missed work hours out of the total; scale 0-100%), Presenteeism (level of work impairment; scale 0-10), Overall work impairment (combination of absenteeism and presenteeism; scale 0-100%), and Activity impairment (impairment in daily activities; scale 0-10).

    Time frame: Baseline to Month 3

  9. Sleep Quality

    Sleep quality will be assessed with the question, "On average, about how many hours of sleep do you get per night?" with responses including "7-9 hrs", "6-6.9 hrs", "5-5.9 hrs" or "less than 5 hrs". The recall period will be 1 week.

    Time frame: Baseline to Month 3

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — If the results of the study are published in the public domain, only aggregate/group data will be published.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2028, 34 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 34 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Sep 2024 → May 2025, primary completion Dec 2025 → Mar 2028 and completion Dec 2025 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 24, 2024
StartActual
May 5, 2025was Sep 2024
Primary completionEst.
Mar 2028was Dec 2025
CompletionEst.
Mar 2028was Dec 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Sep 30, 2026
Start date
Sep 30, 2024→May 5, 2025 (actual)
Sep 30, 2026
Primary completion
Dec 30, 2025→Mar 2028
Sep 30, 2026
Study completion
Dec 30, 2025→Mar 2028
Sep 30, 2026
Contact
No study contact listed any more: removed j•••@healthtechconnex.com · •••1945
Sep 30, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Royal Columbian Hospital · New Westminster, CanadaContact removed V•••@fraserhealth.caContact removed (no phone or email listed)
  • Surrey Memorial Hospital · Surrey, CanadaContact removed v•••@fraserhealth.caContact removed (no phone or email listed)
Sep 30, 2026
Sponsor
Collaborators added: Royal Columbian Hospital Foundation·Surrey Memorial Hospital (SMH)·Centre for Neurology Studies, Canada; collaborators removed: Centre for Neurology Studies, Surrey Neuroplasticity Clinic Inc.·Royal Columbian Hospital·Surrey Memorial Hospital
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Sep 30, 2024→May 5, 2025 (now actual)
    Primary completion Dec 30, 2025→Mar 2028
    Study completion Dec 30, 2025→Mar 2028
    Sponsor Collaborators added: Royal Columbian Hospital Foundation·Surrey Memorial Hospital (SMH)·Centre for Neurology Studies, Canada; collaborators removed: Centre for Neurology Studies, Surrey Neuroplasticity Clinic Inc.·Royal Columbian Hospital·Surrey Memorial Hospital
    Contact No study contact listed any more: removed j•••@healthtechconnex.com · •••1945
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Royal Columbian Hospital · New Westminster, CanadaContact removed V•••@fraserhealth.caContact removed (no phone or email listed)
    • Surrey Memorial Hospital · Surrey, CanadaContact removed v•••@fraserhealth.caContact removed (no phone or email listed)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06428838
Lead sponsor
Dr George Medvedev
Collaborators
H. Lundbeck A/S, Royal Columbian Hospital Foundation, Surrey Memorial Hospital (SMH), Centre for Neurology Studies, Canada
Responsible party
Dr George Medvedev (Principal Investigator, HealthTech Connex Inc.) — Sponsor-investigator
First posted
May 24, 2024
Start date
May 5, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion